![Julien Mazieres on X: "PACIFIC-6 trial #ELCC22 Durvalumab after sequential CRT in unresectable stage III #NSCLC had a similar safety profile to that observed with after cCRT in the PACIFIC trial + Julien Mazieres on X: "PACIFIC-6 trial #ELCC22 Durvalumab after sequential CRT in unresectable stage III #NSCLC had a similar safety profile to that observed with after cCRT in the PACIFIC trial +](https://pbs.twimg.com/media/FPMDM4hWYAMvKUm.png:large)
Julien Mazieres on X: "PACIFIC-6 trial #ELCC22 Durvalumab after sequential CRT in unresectable stage III #NSCLC had a similar safety profile to that observed with after cCRT in the PACIFIC trial +
![Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) - ScienceDirect Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525730421001443-gr3.jpg)
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) - ScienceDirect
![Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) - ScienceDirect Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525730421001443-gr2.jpg)